BTIG Research Issues Positive Forecast for LifeStance Health Group (NASDAQ:LFST) Stock Price

LifeStance Health Group (NASDAQ:LFST) had its target price hoisted by equities researchers at BTIG Research from $9.00 to $10.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research’s target price would suggest a potential upside of 47.93% from the company’s current price.

LFST has been the subject of several other reports. UBS Group increased their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th. BMO Capital Markets started coverage on LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price objective for the company. Zacks Research downgraded shares of LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Barclays initiated coverage on shares of LifeStance Health Group in a report on Tuesday. They set an “overweight” rating and a $8.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.00.

LifeStance Health Group Price Performance

LFST stock opened at $6.76 on Friday. The stock has a market cap of $2.63 billion, a price-to-earnings ratio of -225.33 and a beta of 1.13. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.58 and a quick ratio of 1.58. The company has a 50 day simple moving average of $5.81 and a 200 day simple moving average of $5.33. LifeStance Health Group has a 1 year low of $3.74 and a 1 year high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, November 5th. The company reported $0.02 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. The firm had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. LifeStance Health Group had a negative net margin of 0.67% and a negative return on equity of 0.62%. The company’s quarterly revenue was up 16.3% on a year-over-year basis. During the same quarter last year, the business posted ($0.02) earnings per share. Research analysts anticipate that LifeStance Health Group will post -0.18 EPS for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, insider Lisa K. Miller sold 57,240 shares of the stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $6.43, for a total transaction of $368,053.20. Following the completion of the sale, the insider owned 261,292 shares of the company’s stock, valued at approximately $1,680,107.56. This represents a 17.97% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LFST. US Bancorp DE increased its position in shares of LifeStance Health Group by 1,644.7% during the first quarter. US Bancorp DE now owns 31,718 shares of the company’s stock worth $211,000 after buying an additional 29,900 shares during the period. Vanguard Group Inc. lifted its holdings in LifeStance Health Group by 5.0% in the first quarter. Vanguard Group Inc. now owns 11,221,237 shares of the company’s stock valued at $74,733,000 after buying an additional 531,841 shares during the period. Charles Schwab Investment Management Inc. boosted its position in LifeStance Health Group by 4.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,162,136 shares of the company’s stock valued at $7,740,000 after acquiring an additional 48,637 shares during the last quarter. Invesco Ltd. grew its holdings in LifeStance Health Group by 1.4% during the 1st quarter. Invesco Ltd. now owns 164,384 shares of the company’s stock worth $1,095,000 after acquiring an additional 2,238 shares during the period. Finally, Entropy Technologies LP raised its position in shares of LifeStance Health Group by 112.8% in the 1st quarter. Entropy Technologies LP now owns 43,389 shares of the company’s stock worth $289,000 after acquiring an additional 22,998 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company’s stock.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.